Gabather AB (publ) Total Assets
Gabather AB (publ) total assets. Based on the latest financial reports, Gabather AB (publ) (GABA) holds total assets worth Skr7.01 Million SEK (≈ $754.93K USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see GABA company net worth for the company's overall valuation and market capitalisation.
Total Assets of Gabather AB (publ) (2014–2025)
Total assets of Gabather AB (publ) from 2014 to 2025. This chart illustrates how Gabather AB (publ)'s total assets have evolved over time, based on quarterly financial data. See GABA stock price for real-time trading data and today's change.
Gabather AB (publ) - Asset Composition Analysis
Gabather AB (publ) Total Assets Breakdown (December 2025)
Gabather AB (publ) total assets breakdown as of December 2025. Gabather AB (publ)'s total assets of Skr7.01 Million consist of 98.7% current assets and 1.3% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr3.14 Million | 82.1% |
| Accounts Receivable | Skr637.00K | 16.6% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Gabather AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore GABA working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gabather AB (publ)'s current assets represent 98.7% of total assets in 2025, an increase from 93.0% in 2014.
- Cash Position: Cash and equivalents constituted 82.1% of total assets in 2025, down from 87.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 6.0% in 2014.
- Asset Diversification: The largest asset category is cash and equivalents at 82.1% of total assets.
Gabather AB (publ) Competitors by Total Assets
Key competitors of Gabather AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Gabather AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.66 | 1.06 | 8.07 |
| Quick Ratio | 1.66 | 1.06 | 8.33 |
| Cash Ratio | 0.00 | 0.92 | 7.81 |
| Working Capital | Skr2.77 Million | Skr326.00K | Skr20.23 Million |
Gabather AB (publ) - Advanced Valuation Insights
This section examines the relationship between Gabather AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.71 |
| Latest Market Cap to Assets Ratio | 0.34 |
| Asset Growth Rate (YoY) | 108.9% |
| Total Assets | Skr3.83 Million |
| Market Capitalization | $1.31 Million USD |
Valuation Analysis
Below Book Valuation: The market values Gabather AB (publ)'s assets below their book value (0.34x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Gabather AB (publ)'s assets grew by 108.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Gabather AB (publ) (2014–2025)
The table below shows the annual total assets of Gabather AB (publ) from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr3.83 Million ≈ $412.17K |
+108.95% |
| 2024-12-31 | Skr1.83 Million ≈ $197.26K |
-75.11% |
| 2023-12-31 | Skr7.36 Million ≈ $792.48K |
+9.06% |
| 2022-12-31 | Skr6.75 Million ≈ $726.62K |
-56.13% |
| 2021-12-31 | Skr15.39 Million ≈ $1.66 Million |
-52.14% |
| 2020-12-31 | Skr32.16 Million ≈ $3.46 Million |
-30.19% |
| 2019-12-31 | Skr46.07 Million ≈ $4.96 Million |
+153.66% |
| 2018-12-31 | Skr18.16 Million ≈ $1.95 Million |
-62.30% |
| 2017-12-31 | Skr48.18 Million ≈ $5.18 Million |
+38.66% |
| 2016-12-31 | Skr34.75 Million ≈ $3.74 Million |
+157.14% |
| 2015-12-31 | Skr13.51 Million ≈ $1.45 Million |
+47.51% |
| 2014-12-31 | Skr9.16 Million ≈ $985.78K |
-- |
About Gabather AB (publ)
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. The company focuses on developing GT-002, a pro-cognitive drug candidate for the treatment … Read more